Mylan has seen its sales slump in Europe and in the rest of the world in the second quarter of 2020 due to COVID-19, balancing out the additional demand that had been seen by the company in the first quarter. (Also see "Mylan Delays Restructuring Amid COVID-19" - Generics Bulletin, 14 May, 2020.)
Mylan Sees COVID-19 Impact On Sales
Also Exploring International Listings For Viatris After Upjohn Merger
Mylan has seen its second-quarter performance echo that of its industry peers, with a lift provided by COVID-19 related demand in the first three months of the year balanced out by declines in the second quarter of 2020.
More from Earnings
More from Business
• By
Cipla will look to give its US operations a boost later this year by launching only the second Abraxane ANDA product.
• By
The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.
• By
Henlius has reported progress in its development of a bevacizumab product for treating ophthalmic diseases, with its Essex-partnered HLX04-O candidate meeting its primary endpoint in a Phase III trial. Meanwhile, Outlook Therapeutics has taken another shot at getting its own ophthalmic bevacizumab approved in the US after resubmitting its filing.